sustain 9 semaglutide semaglutide showed a statistically significant 26% risk reduction - SUSTAIN11 semaglutide 1.0 mg The SUSTAIN 9 Trial: Unpacking Semaglutide's Efficacy as an Add-on Therapy for Type 2 Diabetes

SUSTAIN10 trial The SUSTAIN 9 trial represents a significant contribution to understanding the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, particularly when used as an add-on therapy for individuals with type 2 diabetes. This double-blind, placebo-controlled study, a component of the broader SUSTAIN clinical trial program conducted by Novo Nordisk, specifically investigated the benefits of once-weekly semaglutide in patients whose glycemic control was inadequately managed with existing sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy.

Expertise and Experience in Diabetes Management: The Foundation of SUSTAIN 9

The field of diabetes management is continuously evolving, and robust clinical trials are paramount in guiding therapeutic decisionsNCT03086330 | Efficacy and Safety of Semaglutide Once- .... The SUSTAIN 9 trial builds upon a wealth of research and clinical experience with semaglutide and related compounds.Novo Nordisk A/S: CagriSema demonstrated 23% weight ... Leading the investigation were researchers like B. Zinman, V. Woo, and other esteemed medical professionals, bringing their extensive knowledge in endocrinology and diabetes care to the forefront. Their collective expertise ensures the trial's design, execution, and interpretation are grounded in sound scientific principles and a deep understanding of the challenges faced by patients with type 2 diabetes佛历2562年3月4日—InSUSTAIN 9, adults with type 2 diabetes were randomized to receive once-weeklysemaglutideor placebo in addition to an SGLT-2i, either as .... The SUSTAIN 9 trial was conducted across 61 centers in six countries, including Austria, Canada, Japan, Norway, Russia, and the USA, demonstrating a global commitment to advancing diabetes treatment.

Delving into the SUSTAIN 9 Methodology and Findings

The core objective of SUSTAIN 9 was to assess the impact of adding semaglutide to an established SGLT-2 inhibitor regimen. Participants were randomized to receive either semaglutide 1.Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9): a randomised, placebo-controlled trial. Zinman B, Bhosekar V ...0 mg versus placebo (or semaglutide 1.作者：B Zinman·2019·被引用次数：413—Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes ...0 mg vs. placebo as it's also described) administered once weekly, in addition to their stable dose of an SGLT-2 inhibitor. This approach aimed to isolate the specific benefits of semaglutide when introduced to this particular background therapy.

The results, published in reputable journals such as The Lancet Diabetes & Endocrinology, revealed significant and clinically relevant reductions in key metabolic markers.作者：B Zinman·2019·被引用次数：413—Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes ... Specifically, patients receiving semaglutide 1.0 mg experienced a greater reduction in their glycated hemoglobin (HbA1c) levels compared to those on placebo.Semaglutide once weekly as add-on to SGLT-2 inhibitor ... HbA1c is a critical indicator of long-term blood sugar control, and lowering it is fundamental in managing type 2 diabetes and mitigating its associated complicationsNovo Nordisk reports positive results from SUSTAIN 9 trial. Furthermore, the trial demonstrated that semaglutide also contributed to a reduction in body weight.Efficacy of Semaglutide by Background Sodium-Glucose ... This dual benefit of improved glycemic control and weight management is particularly valuable for many individuals with type 2 diabetesNovo Nordisk A/S: CagriSema demonstrated 23% weight ....

The consistent findings across various analyses, including those examining the efficacy by background sodium-glucose cotransporter-2 inhibitor, underscore the reliability of semaglutide's performance in this setting. These results are consistent with the broader SUSTAIN program, which has consistently shown positive outcomes for semaglutide across different patient populations and treatment regimens. For instance, the SUSTAIN-6 trial previously highlighted that semaglutide demonstrated a statistically significant 26% risk reduction in major adverse cardiovascular events (MACE) in older adults with type 2 diabetes5天前—Recent trials have shown thatsemaglutide reduces the risk of heart attack, stroke, and deathfrom atherosclerotic cardiovascular disease (ASCVD) .... This adds a crucial cardiovascular safety dimension to the understanding of semaglutide's benefits.

Beyond Glycemic Control: Broader Implications and Related Research

The implications of the SUSTAIN 9 trial extend beyond immediate glycemic improvementsSemaglutide once weekly as add-on to SGLT-2 inhibitor .... Semaglutide has also shown promise in other areas related to metabolic health. Although not the primary focus of SUSTAIN 9, the broader impact of GLP-1 receptor agonists, including semaglutide, on cardiovascular health has been a significant area of research. Recent findings suggest that semaglutide reduces the risk of heart attack, stroke, and death from atherosclerotic cardiovascular disease (ASCVD). This broader context is vital for a comprehensive understanding of the drug's potentialSemaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9): a randomised, placebo-controlled trial. BZBernard Zinman..

The data from SUSTAIN 9 also aligns with other investigations into semaglutide, such as its use in overweight or obese individualsSemaglutide once weekly as add-on to SGLT-2 inhibitor .... Studies like the one by Wilding et al. have shown that once-weekly semaglutide plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. In fact, some new formulations and combinations, like CagriSema, have demonstrated remarkable results, with CagriSema achieved 23% weight loss after 84 weeks of treatment in specific studies, indicating ongoing advancements in weight management therapies.

It is important to note that while semaglutide has proven effective in various trials, including those within the SUSTAIN framework, research continues to explore its full potential and address specific patient needs. Discussions around weight regain after GLP-1-based therapy discontinuation are ongoing, emphasizing the need for sustained adherence and individualized treatment plans.作者：B Zinman·2019·被引用次数：413—TheSUSTAIN 9double-blind, parallel-group trial was done at 61 centres in six countries (Austria, Canada, Japan, Norway, Russia, and the USA).

In summary, the SUSTAIN 9 trial provides robust evidence supporting the addition of semaglutide to SGLT-2 inhibitor therapy for individuals with type 2 diabetes who require enhanced glycemic control. The trial's rigorous methodology, expert-driven approach, and significant findings contribute valuable insights to the ongoing efforts to improve the lives of those living with diabetes.